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Abstract Anew iron-basedT1 contrast agent consist-
ing of a complex of iron ions coordinated to phosphate
and amine ligands (Fe(phos) in short) has been charac-
terized by spectroscopic and magnetic measurements.
NMR relaxation studies showed r1 values to be depen-
dent on the phosphate salt concentration, K2HPO4,
present in the medium. r1 reaches a maximum value of
2.5mM−1 s−1 for measurements carried out at 7T and
298K. 31P MRS, Mössbauer spectroscopy and magnetic
measurements of Fe(phos) solutions suggest paramag-
netic Fe3+ ions present in the studied iron–phosphate
complex. In vitro and in vivo toxicity experiments with
C6 cells and CD1 mice, respectively, demonstrated lack
of toxicity for Fe(phos) at the highest dose tested in
the MRI experiments (12mM iron for C6 cells and
0.32mmol iron/kg formice). Finally,T1 weighted images
of brain tumours in mice have shown positive contrast
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enhancement of Fe(phos) for tumour afflicted regions in
the brain.
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Introduction
Magnetic resonance imaging (MRI) is one of the most
powerful techniques in clinical diagnostic medicine and
in non-invasive biomedical research andhas fostered the
development of agents designed to enhance tissuediffer-
entiation in vivo. The effect of these agents, mainly com-
plexes of Gd3+, Fe3+, and Mn2+, is known to improve
contrast inMR-based images (1,2).MRI contrast agents
(CA) act by accelerating the relaxation process of water
protons in tissues by selectively decreasing both the
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longitudinal relaxation time, T1, and the transversal
relaxation time,T2.Gd3+ complexes have receivedmost
attention as contrast agents for MRI applications due
to their large magnetic moment and a suitable long
electronic relaxation time. However, there is no natu-
ral human biochemistry for Gd3+ that can be exploited
when designing its contrast agents derivates (3–6). On
the other hand, agents based on Mn2+, Fe3+, and Cu2+
ions are attractive alternatives (7–9) because these met-
als are already present in tissues and there is extensive
information available about their human biochemistry,
including transport, storage, compartmentalization and
excretion mechanisms. Many of the iron-based contrast
agents consist of superparamagnetic particles of col-
loidal iron oxides that cause T2-enhancement (10,11).
A second type of iron-based contrast agents are iron(III)
mononuclear complexes. In this case the ligands provide
coordinative saturation to the iron, avoiding the occur-
rence of Lewis acid-catalyzed hydrolysis reactions and
redox processes (12), toxic to the body and which are
potentially facilitated by free Fe3+ ions. Furthermore,
Fe3+ ionsmust be chelated to avoid precipitation caused
losses near pH ∼7.
The complex [(tacn)6Fe8(µ3-O)2(µ2-OH)12]Br8 ·
9H2O, where tacn = 1,4,6-triazacyclononane, and here-
after referred to as Fe8, was chosen by us in order to
study its potential as contrast agent (13). Due to the size
of Fe8 molecules, the distribution and residence time in
the tissues should be different and produce complemen-
tary information to that given by Gd-based chelates and
iron oxide nanoparticles. A major shortcoming of clin-
ical and experimental MR contrast agents is that they
are limited to reporting anatomic detail only. Neverthe-
less, significant progress has been made on the design
and preparation of MR agents that are brighter, selec-
tively targeted and have a longer residence time in vivo
(14,15).
In this work, we present the unexpected relaxometric
properties of the solutions obtained by adding a known
amount of the Fe8 molecule to phosphate salt solutions
at different concentrations of K2HPO4, and hereafter
referred as Fe(phos). Spectroscopic and magnetic stud-
ies of the Fe(phos) solutions were also carried out. The
results have shown the instability of the Fe8 precursor
in phosphate solutions and the formation of a new time-
stable species, Fe(phos), rapidly established among the
Fe3+ ions and amine ligands present in the Fe8 clus-
ter and phosphate ions. Therefore we hypothesized that
the new contrast agent described in this work could
be potentially useful to report on hyperphosphatemic
regions inside a living organism. Before embarking in
such a study, in vivo effect and tolerance need to be
assayed. For this, toxicity studies of Fe(phos) solutions
using C6 glioma cells were carried out. Furthermore,
preliminary in vivo studies were also performed with
mice to evaluate both toxicity, with control animals, and
T1 contrast enhancement for stereotactically induced
brain tumours.
Experimental section
Synthesis of [(tacn)6Fe8(µ3-O)2(µ2-OH)12]Br8 · 9H2O
Reagents were purchased from Sigma Aldrich (Spain)
and used as received without further purification. The
synthesis of Fe8 was performed as described by
Wieghardt et al. (16). A special batch enriched with
57Fe isotope was prepared to be used for theMössbauer
characterization.
NMR relaxation studies
1H measurements were performed on a Bruker Avance
300 spectrometer operating at a magnetic field of 7.0 T
at 298K. Inversion-recovery (180◦x-τ -90◦x-acquire) and
Carr-Purcell-Meiboom-Gill (90◦x-[τ -180◦y-τ ]n-acquire)
pulse sequenceswereused tomeasureT1 andT2, respec-
tively. Five millimeter-diameter NMR tubes, each con-
taining deuterated water (used for locking purposes)
and a capillary tub insert filled with the iron aqueous
solutions, were used essentially as in (13). Relaxation
time constants were obtained by fitting the proper equa-
tion to thepeak areadata using a least-squares algorithm
as implemented in the processing Bruker software. Cor-
relation coefficients greater than 0.9 were obtained in
all cases.
T1 relaxation measurements at 0.24T and 298Kwere
performed on a Spinmaster FFC, fast field cycling,
Stelar, in the following range 0.00024–0.24T. Three
independent experiments were measured for each con-
centration, and each data point corresponds to one
experiment.
Fe(phos) solutions were prepared with 2mg/ml of Fe8
in phosphate solutions ranging from 0.01 to 1M of K2
HPO4 salt, at neutral “(7)” and basic “(12)” pH. Relax-
ivities values are referred to moles of Fe, where 1mM
Fe8 equals 8mM Fe.
Spectroscopic and magnetic characterization
31P spectra of Fe(phos) were performed on a Bruker
Avance300 spectrometer operating at a magnetic field
of 7.0 T, at 298Kwith 5mm tubes. Spectra of the Fe(phos)
were obtained from four samples of a solution 0.5ml of
10mg/ml of Fe8 in 0.005, 0.01, 0.25 and in 1M aqueous
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phosphate solutions, respectively, at neutral pH (7 <pH
<7.4). 31P spectrumof theK2HPO4 salt in aqueous solu-
tion was also recorded. 2H2O was used for locking pur-
poses and H3PO4 (85%) as external reference.
Mössbauer spectra of Fe(phos) and the Fe8 powder,
hereafter referred as Fe8(s), were recorded at 4.2K with
a conventional transmission spectrometer using a 57Co
source in Rh matrix. Calibration was carried out using
a 25-µm thick natural iron foil. Spectra of the Fe(phos)
were obtained from two samples of a frozen solution
0.5ml of 10mg/ml of 57Fe8 in 0.05M and in 1M phos-
phate solutions, respectively, at neutral pH.
The temperature dependences of dc magnetization
for the frozen phosphate solution and the Fe8(s), sam-
ples weremeasuredwith a PPMSmagnetometer (Quan-
tum Design) over the temperature range 2–250K in an
applied field up to 90 kOe. The experimental results
were corrected for the holder contribution as well as for
a temperature independent diamagnetic contribution.
For the magnetic studies two solutions of 10mg/ml of
Fe8 in 0.05 and 1M were prepared at neutral pH. All
the magnetization data are presented in emu/mol Fe.
Cells and animals
The C6 cell line from rat glioma was obtained from the
European Collection of Cell Cultures (ECACC). Cells
weremaintained inHam’s F-12 supplemented with 10%
foetal bovine serum, 2mM glutamine and 50µM gen-
tamicin. C6 glioma cells were grown in culture flasks
and passed every 3–4 days. GL261 mouse glioma cells
were obtained from the Tumour Bank Repository at
the National Cancer Institute, Frederick, USA and con-
stitute a well-established experimental glioma model
in mice (17). These were grown in RPMI-1640 culture
medium supplemented with 2.0 g/l sodium bicarbonate,
0.285 g/l L-glutamine, 10% foetal bovine serum (Gibco)
and 1% penicillin–streptomycin Solution. Culture
medium and chemicals were purchased from Sigma
unless otherwise indicated. Culture plastic was obtained
from Nunc.
Thirty CD1 mice (Charles-River Labs., France) with
weights between 24 and 36 g, were used for toxicity
studies. MRI studies were performed with mice har-
bouring a brain tumour, which is a classic pathology
model to demonstrate T1 contrast effect in vivo (18).
For this we implanted a total of seven mice with murine
glioma cells: six with GL261 cells (mice 1–6) (18) and
one with C6 cells (mouse 7) (19). Briefly, animals were
anesthetized intraperitoneal (i.p.) with ketamine–xyla-
sine, 80–10mg/kg, and then immobilized on a stereo-
tactic holder (Kopf Instruments, Tujunga, CA, USA).
After the scull was exposed, a 1.0mm hole was made
2.3mm lateral (right) to the midline, as measured from
theBregma. A 26GHamilton syringe (Reno/NV,USA),
positioned on a digital push-pull microinjector (Harvard
Apparatus, Holliston, MA, USA) was then advanced
2.3mm from the cortical surface into the striatum, and
4µl RPMI medium containing 105 GL261 (or C6) cells
were injected at a rate of 2µl/min. Three to five min-
utes after the injection had finished, the syringe was
slowly removed, the scission site closed with suture silk
(5.0) and the animal left to recover in a warm envi-
ronment (about 25◦C). Toxicity studies were conducted
at the animal facility of the University of Barcelona,
where animals were housed. For in vivo tumour stud-
ies, animals were housed first at the animal facility of
Universitat Autònoma de Barcelona (Servei d’Estabu-
lari), where tumour cells were stereotactically injected,
and then transported to the Instituto de Investigaciones
Biomedicas “Alberto Sols” UAM-CSIC, Madrid, where
MR studies were conducted. Animals were always fed
ad libitum, allowed 12–12 h light–dark cycles and were
treated according to protocols approved by the animal
healthcare committee of each relevant institution.
Toxicity studies
In vitro
For cytotoxicity assays, cells from the C6 glioma cell
line were seeded in 12-well plates and treated for 72 h
with the Fe(phos). We used the lactate dehydrogenase
(LDH) leakage test that indicates the presence of cell
membrane damage (20). In a previous work we have
determined the reliability of LDH test for analyzing Fe8
cytotoxicity (13). Using a spectrophotometric NADH
consumption assay, in the presence of pyruvic acid sub-
strate, LDH leaked from cells was measured in the cul-
ture medium after 72 h exposure to Fe(phos) solutions
and expressed as the change in optical density per min
(OD/min).
In vivo
According to spectroscopy and magnetic characteriza-
tion results obtained previously in vitro (seeResults sec-
tion), Fe(phos) solutions were prepared at a ratio
[HPO2−4 ]/[Fe8] of 10, pH 7.2. In vivo toxicity of these
Fe(phos) solutions was evaluated in CD1 mice. Different
dose levels were administrated by intravenous (i.v.) tail
injection with a volume of 4µl/g. The study was per-
formed with groups of five males and five females per
dose. Animals were regularly monitored for two weeks
30 Magn Reson Mater Phy (2007) 20:27–37
after the injection of Fe(phos). After that, all surviving
animals were sacrificed and autopsied.
MRI studies
Seven mice harbouring a brain tumour were used for
MRI studies. Thesewere carried out at 7.0 T on aBruker
PharmaScan 70/16 (SIERMAC,UAM-CSIC), equipped
with active shielded gradients, 300mT/m, and a 30-mm
proton RF coil, optimized for the mouse head. Anaes-
thesia was performed with isoflurane at 1–2.5% in O2
and the respiratory frequency maintained between 40
and 60 breaths/min. Animals were also thermostatized
with a heated water blanket during this procedure.
Before immobilization in the MR holder each animal
was canulated in the tail vein (i.v.) with a 26G
Abbocath-T. For both, animal scanner time economy
and to be able to compare the differential effect of the
two contrast agents, avoiding at the same time poten-
tial interferences of different tumour vascularization on
each animal, both Fe(phos) and Gd-DTPA were used in
the same experiment with each animal. After detecting
each tumour by T2 weighted imaging, Dynamic contrast
enhancedT1 (DCE-T1)MRIwas performed in the slices
of interest along with the iv bolus injection of either
Gd-DTPA or Fe(phos) solution, both at 4µl/g. Assuming
an approximate 1:11.8 dilution of each contrast agent
when spreading into the blood pool of each mice after
injection (calculations explained in more detail ahead
in the Discussion section), the Fe(phos) dose used in
these studies was always kept below those described
as non-toxic from both in vivo and in vitro toxicol-
ogy analysis (1mM and 0.04mmol/kg, respectively, see
Results section). Order of injection in mice harbour-
ing GL261 tumours was Fe(phos) (0.04mmol Fe8/kg) fol-
lowed by Gd-DTPA (mice 1–5: 0.2mmol/kg; mouse 6:
0.04mmol/kg) after 2 h 30min–3 h washout period. As
for mouse 7, implanted with C6 cells, Gd-DTPA was
injected first (0.2mmol/kg) and, 4 h later, the Fe(phos)
solution (0.04mmol Fe8/kg). In all cases, the second
contrast agent was not injected until there was a visual
washout confirmation of the previous one in T1 control
images. Acquisition parameters for T2 weighted images
were: RARE sequence; turbo factor, 8; field of view
(FOV), 20 × 20mm; matrix (MTX), 256 × 256 (78 ×
78µm/pixel); number of slices (NS), 14; slice thickness
(ST), 1mm; interslice-thickness (IST), 1.1mm
TR/TE=2,500/60ms; number of averages (NEX), 4;
total acquisition time (ACQ), 5m 20 s. For DCE-T1:
MSME sequence; FOV, 21 × 21mm; MTX, 128 × 128
(164 × 164µm/pixel); NS, 3; ST, 1mm; IST, 1.1mm;
TR/TE, 200/9ms; NEX, 1; number of images acquired
for each slice (NR), 40; ACQ, 34m 8 s (51 s 200ms per
slice group episode); bolus injection of the CA during
acquisition of the second image. DCE-T1 images were
then processed with IDL (RSI, France) home written
scripts to generate time-course curves that quantified
the average contrast enhancement inside the tumours
(defined from regions of interest, ROIs). ImageJ free-
ware software was also used to obtain fusion images
(T2 control images overlapped with colour coded
CE-T1 data).
Results
NMR relaxometric studies
The dependence of relaxivities r1 and r2 with the concen-
tration of K2HPO4 for a given initial Fe8 concentration
of 1mM (8mM of Fe) at 7.0 T is shown in Fig. 1. The T1
and T2 values were converted to relaxivity in mM−1 s−1
Fe by taking into account the dilution factor used. An
increase of r1 and r2 was observed as the concentration
of phosphate salt increased. The time stability of the r1
and r2 values was checked by repeating the r1 and r2
measurements at several times (2, 8, 24 and up to 100 h).
While no relaxivity time changes were observed for a
K2HPO4 to Fe8 molar ratio, [HPO2−4 ]/[Fe8], equal or
higher than 10, for lower concentrations of K2HPO4, r1
and r2 values decreased with time (results not shown).
The dependence of r1 with the K2HPO4 concentration
at 0.24T has been measured at basic and neutral pH
values (see inset in Fig. 1). The r1 value at basic pH
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Fig. 1 Relaxivities, r1 and r2, dependence with the concentra-
tion of K2HPO4 for a given initial Fe8 concentration of 1mM at
7.0 T and 298K. Three independent experiments were measured
for each concentration, and each data point corresponds to one
experiment. r1 dependence with the concentration of K2HPO4 at
0.24T at pH values of 7 and 12 is shown in the inset
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is essentially constant for all phosphate concentrations
and has a value comparable with themaximum achieved
at neutral pH. The different behavior of r1 at basic and
neutral pH values is more evident for lower K2HPO4
concentrations such as [HPO2−4 ] = 0.01M, where the
r1 value increases from 0.8mM−1 s−1, at neutral pH, to
2.8mM−1 s−1, at a basic one.
Spectroscopic and magnetic characterization
Spectroscopic and magnetic characterization were car-
ried out in order to increase our understanding of the
type of interaction of the phosphate ligands and the
iron ions in Fe(phos). For this purpose several solutions
with different [HPO2−4 ]/[Fe8] ratios were prepared. 31P
spectra of these solutions are shown in Fig. 2. As the
K2HPO4 concentration increases, there is a rise in the
apparent peak intensity at about 2.5 ppmwith respect to
baseline noise, which corresponds to freeK2HPO4.Nev-
ertheless, for ratios of [HPO2−4 ]/[Fe8] lower than ten, no
resonance was detected suggesting a strong interaction
between the phosphate ligands and the iron ions.
Moreover, for a given initial concentration of Fe8 the
magnetic properties andMössbauer spectroscopy of two
Fe(phos) samples, with low (0.05M), [HPO2−4 ]/[Fe8] =
10, and high (1M), [HPO2−4 ]/[Fe8] = 500, concentration
of phosphate salt were carried out. Mössbauer spectra
of Fe(phos) at 4.2K are shown in Fig. 3a and b. In the
samemanner,Mössbauer spectrumof the powered sam-
ple, Fe8(s), was recorded for comparison (Fig. 3c). The
differences between the three spectra are evident. For
0.05M K2HPO4 (Fig. 3a) the spectrum could be fitted
using two symmetrical doublets while for 1M K2HPO4
Fig. 2 31P spectra of Fe(phos) solutions with [K2HPO4] =
0.005, 0.01, 0.25 and 1M, respectively and of 0.1M K2HPO4 salt
at 7.0 T, 298K and at neutral pH (7 < pH < 7.4)
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Fig. 3 Mössbauer spectra for Fe(phos) and Fe8(s) at 4.2K;
a corresponds to Fe(phos) for concentration [K2HPO4] =
0.05M, [HPO2−4 ]/[Fe8] = 10; b corresponds to Fe(phos) for con-
centration [K2HPO4] = 1M, [HPO2−4 ]/[Fe8] = 500 and c corre-
sponds to Fe8(s)
(Fig. 3b) the spectrum could be fitted using three sub-
spectra; two symmetric doublets and amagnetically split
sextet accounting for about 25%of the total area.On the
contrary, the precursor molecule Fe8(s) (Fig. 3c) shows a
completely resolved spectrum indicating that all spins
are frozen in a collective state and no paramagnetic
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phase, that would lead to a central doublet, or singlet
is detected. The results obtained from Mössbauer spec-
troscopy for the two Fe(phos) samples suggest: (1) in both
cases the iron is found as Fe3+ species, and (2) for the low
phosphate sample, 0.05M K2HPO4, a typical paramag-
netic or superparamagnetic behaviour is observed while
for the concentrated sample, 1M K2HPO4, a fraction
of the iron ions (25%) becomes magnetically coupled
at low temperatures in agreement with the formation
of an oligomeric species (21). Magnetic characterization
was carried out to complementMössbauer spectroscopy.
The temperature dependences of χT for Fe(phos) solu-
tions, for 0.05M K2HPO4 and 1M K2HPO4, obtained
in a field of 90 kOe are shown in Fig. 4a, b, which sug-
gest an antiferromagnetic coupling between Fe ions for
both samples. For the powered sample, Fe8(s), the χT(T)
curve measured at 90 kOe is also shown in Fig. 4c. χT
values exhibit a plateau at elevated temperatures, then
a steadily increase on decreasing temperature up to a
certain maximum followed by a rapid decrease indi-
cating that the Fe3+ clusters have ferrimagnetic spin
ordering. Thus, χT(T) dependence obtained for Fe8(s)
is very different from those obtained for Fe(phos) solu-
tions pointing to a re-arrangement of the Fe3+ ions in
the phosphate solution and the appearance of antiferro-
magnetic coupling between Fe ions.
Toxicity studies
Hereafter the Fe(phos) doses used for the described stud-
ies have been prepared maintaining a ratio [HPO2−4 ]/[Fe8] ≥ 10, in order to assure the stability of the newly
formed complex in aqueous solution.
In vitro
The effects of Fe(phos) treatment on cell viability in the
C6 glioma cell line were studied after exposures of 72 h
duration. For this, the standard cell culture medium was
replaced by media containing the Fe(phos) solutions. The
range of concentrations of Fe8 studied was 0.1–1mM
and the concentration of phosphate added was 10mM.
Stock solutions pH was adjusted to neutral pH. Figure 5
shows the LDH released by increasing mM concentra-
tions of Fe8. No cytotoxicity effects of Fe(phos) were
detected in C6 cell cultures in the whole range of con-
centrations tested.
In vivo
The toxicity assay of Fe(phos) solution in mice after i.v.
injection was performed at doses of 0.04, 0.06 and
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
χ*
T 
[em
uK
/m
olF
eO
e]
a)
b)
c)
0 100 150 200 250
0.0
0.5
1.0
1.5
2.0
2.5
3.0
χ*
T 
[em
uK
/m
olF
eO
e]
T [K]
0.0
1.0
2.0
3.0
4.0
5.0
χ*
T 
[em
uK
/m
olF
eO
e]
50
0 100 150 200 250
T [K]
50
0 100 150 200 250
T [K]
50
Fig. 4 Temperature dependence of the susceptibility measured
at H = 90 kOe-χgT versus T for: a Fe(phos) for concentration
[K2HPO4] = 0.05M, [HPO2−4 ]/[Fe8] = 10; b Fe(phos) for concen-
tration [K2HPO4] = 1M, [HPO2−4 ]/[Fe8] = 500 and c Fe8(s)
0.08mmolFe8/kgbodyweight, and the concentrations of
phosphate added were 0.4, 0.6 and 0.8mmol/kg, respec-
tively. The lower dose resulted in 100% survival (ten
animals); the middle dose resulted in 80% survival (four
animals out of five of each sex survived); and the higher
dose tested resulted in 60% survival (three animals out
of five of each sex survived). Death happened either
briefly after the injection when preceded by convulsion
or it was delayed several days and then preceded by
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Fig. 5 Concentration–response cytotoxicity curves. LDH leaked
from the cells in the presence of Fe(phos) solutions, with 10mM of
K2HPO4 added. Three independent experiments were measured
for each concentration, and each data point corresponds to one
experiment
a period with activity depression, ataxia and reduced
animal response to stimulation. No significant abnor-
mal findings were observed at the macroscopic autoptic
analysis for any of the sacrificed animals.
MRI studies
As shown in Fig. 6, all DCE-T1 studies performed
with Fe(phos) solutions produced a positive contrast-
enhancement in brain tumours, both for GL261 (mice
1–5, 12 time-course curves:maximum114±5%—Fig. 6a;
mouse 6, 3 time-course curves: maximum 118 ± 3%—
Fig. 6b) and for C6 (mouse 7, 3 time-course curves:
maximum 123 ± 9%—Fig. 6c), as compared to refer-
ence T1 control images (100%). This is shown with
CE-T1 images (III), fusion images (IV) and also with
the time-course curves for each contrast agent (V) pre-
sented all together in Fig. 6. Nevertheless, this effect
was always inferior to that obtained with Gd-DTPA,
either at the standard dose (mice 1–5 and mouse 7,
0.2mmol/kg: 177 ± 17% and 184 ± 21%, respectively),
or at an equivalent dose to that of Fe(phos) (mouse 6,
0.04mmol/kg: 130 ± 2%). Also, in most GL261 tumour
cases studied the contrast enhancement achieved with
the Fe(phos) solution was not well distinguished visually
after the first minutes post-injection despite being well
observed in the time-course curves. The only exception
was the single C6 tumour studied, where apparently the
washout period of the Fe(phos) solutionwasmuch longer.
Moreover, Fig. 7 shows the time-course of the intensity
measured in ROIs positioned in the jugular veins (inte-
rior and exterior) after bolus injection of each contrast
agent. Despite the large standard deviations, it is possi-
ble to observe a slightly larger signal enhancement with
Gd-DTPA during the initial minutes post-injection (at
1.8min: 211±121%withGd-DTPA and 161±42%with
Fe(phos) solution) becoming at later times indistinguish-
able among the two compounds, albeit Gd-DTPA seems
to display a tendency to faster clearance fromblood than
Fe(phos).
Discussion
In this work, we have characterized the relaxometric
properties of the Fe3+ ions, originated from the re-
arrangement of the Fe3+ ions from the initial cation
[(tacn)6Fe8(µ3-O)2(µ2-OH)12]8+, [Fe8]8+, and thephos-
phate groups present in phosphate solutions. To our sur-
prise, for a given initial concentration of Fe8, the T1 and
T2 relaxation times of water protons notably dropped
as the concentration of phosphate was increased. For
instance, as the ratio [HPO2−4 ]/[Fe8] was changed from
10 to 1,000, r1 increased from 0.5mM−1s−1 to 2.5mM−1
s−1. Furthermore, it was determined that the ratio
[HPO2−4 ]/[Fe8] must be equal or higher than ten in
order to obtain time-stable relaxometric results. For a
given concentration of Fe8, the large r1 values obtained
at basic pH and its lack of dependence of the phos-
phate/Fe8 ratio suggests a possible role of the PO3−4
species in complex formation with the Fe3+ ions. Nev-
ertheless, further measurements should be performed
to corroborate this assumption. Spectroscopic and mag-
netic measurements of Fe(phos) confirmed that the Fe8
molecule does not remain stable in phosphate solution.
These studies also suggested that the decomposition is
catalysed by the phosphate group, and it is followed by
formation of a stable, possibly colloidal, suspension of
oligomeric species which composition and size is likely
to depend on the ratio between Fe and phosphate. It
shouldbepointedout that noprecipitationwasobserved
at any pH value or [HPO2−4 ]/[Fe8] ratio studied. This is
indicative that the amine groups are present in the final
product, since otherwise Fe3+ hydroxides would have
precipitated, which was not the case. A possible expla-
nation for the observed increase of relaxivity values at
neutral pH as the phosphate concentration is increased
could be that the phosphate anion allows the forma-
tion of a short-lived second coordination complexwhere
these phosphate ligands promote an approximation of
the water protons to the Fe3+ ions. This dynamic process
would be based in the fast exchange of water molecules
near physiologic pH with the complex, which would
allow this relaxivity increase. Increasing the phosphate
concentration would enhance the formation of an olig-
omeric species which in turn, would result in a decrease
of its rotational time. To validate our model, the resolu-
tion of the crystal structure of the new compound in the
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Fig. 6 In vivo MRI studies. Column I, T2 images of the brain
highlighting the tumour. Sections are transversal in A and B and
coronal in C. Columns II and III, DCE-T1 studies: control T1
images previous to bolus injection (II) and first CE-T1 images
acquired in the study at 51m 200 s post-injection (III). Column
IV, fusion of image I with a colour-coded reconstruction of image
III that shows the signal enhancement (red, lowest, to yellow,
highest) only inside the brain. Column V, time–course curves
showing the average signal enhancement in the tumour region
(manually defined by ROIs) after bolus injection of each contrast
agent. a Mouse harbouring a GL261 brain tumour studied first
with Fe(phos) 0.04mmol/kg (II–IV, upper row) and, 2 h later, with
Gd-DTPA 0.2mmol/kg (II–IV, bottom row). Time–course curves
represent the average readings from different slices in mice 1–5
(12 time–course curves for each contrast agent). bMouse harbour-
ing a GL261 brain tumour studied first with Fe(phos) 0.04mmol/kg
(II–IV, upper row) and, 3 h later, with Gd-DTPA 0.04mmol/Kg
(II–IV, bottom row). Time–course curves represent the average
readings (bar ± SD) from three slices in mouse 6 (three time–
course curves for each contrast agent). c Mouse harbouring a
C6 brain tumour studied first with Gd-DTPA 0.2mmol/kg (II–IV,
upper row) and, 4 h later, with Fe(phos) 0.04mmol/kg (II–IV, bot-
tom row). Time–course curves represent the average readings (bar
± SD) from three slices in mouse 7 (three time–course curves for
each contrast agent)
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Fig. 7 Average time
time–course (bar ± SD) of the
intensities measured in ROIs
positioned in the jugular veins
(interior and exterior,
highlighted by white arrows
on the CE-T1 image obtained
with Fe(phos) solution) after
bolus injection of each agent
(CA) in four animals
implanted with GL261 cells
(four ROIs per animal
produce a total of 16 curves)
presence of phosphate groups would be of great help.
However, in spite of the large number of attempts made
using several strategies no acceptable crystals were
obtained.
It may be relevant to mention here early work (27) in
which a polynuclear Fe(III) ·ATP (4:1) stable complex
in solution was demonstrated. The molecular weight
of that complex was in excess of 50,000 Mr and, as in
the case for Fe(phos) at [HPO2−4 ]/[Fe8] ≤ 10, 31P NMR
resonances for ATP were broadened beyond detection,
presumably due to paramagnetic interaction of the
phosphate resonances of ATP with Fe(III). In this
Fe(III) ·ATP complex the N of the purine ring seemed
to participate in complex stabilization. A similar role
could be playing in the Fe(phos) complex herewith stud-
ied the N atoms contributed by the tacn.
Cytotoxicity studies showed lack of toxic effects for a
ratio of [K2HPO4]/[Fe8] ≥ 10, suggesting that there are
no free iron(III) ions in the phosphate solution in con-
trast with their presence detected in aqueous solutions
in which phosphate was absent (22). Our preliminary
DCE-T1MRI studies obtained in vivo demonstrate that
Fe(phos) solutions produce positive contrast enhance-
ment in glioma brain tumours grown in mice at a dose
that presented no toxic effects up to 14 days post-injec-
tion in control animals. Nevertheless, Gd-DTPA is
clearly more efficient as a contrast agent to highlight
blood-brain barrier (BBB) breakdown in brain tumours
than the Fe(phos) solution, producing about five times
more contrast at the highest doses tested here. Tak-
ing into account the fact that both agents produced
an identical signal enhancement in the vascular bed, as
described in Fig. 7, the lower enhancement of tumour
contrast produced by Fe(phos) could possibly be due to a
decrease in the inorganic phosphate (Pi) concentration
in the extracellular tumour compartment with respect
to the Pi concentration in the mouse plasma. In this
respect, Pi concentrations described in the literature for
mouse plasma is in the 0.82–3.08mM range (average
1.95mM), calculated from (23,24). Furthermore, after
Fe(phos) i.v. injection (4µl/g) the plasma Pi levels are
expected to rise to about 10.45mM (assuming 1.1ml of
plasma in a 25 g mouse and an average basal plasma Pi
of 1.95mM). Simultaneously the iron (Fe8) concentra-
tion in plasma coming from Fe(phos) injection would be
expected to be about 0.85mM, therefore producing a
Pi/Fe(phos) ratio higher than ten. This should produce,
as described in the NMR relaxometric studies section,
high r1 values and optimal positive contrast enhance-
ment, as demonstrated from venous blood in Fig. 7. On
the other hand, results shown in Fig. 6 would be coher-
ent with a much lower Pi concentration in the tumour
extracellular fluid than in circulating blood causing a
decreased effect on water relaxivity and, thus, lower
contrast enhancement. Nevertheless, it may be relevant
to compare results obtained with GL261 and C6 cells.
C6 derived rat glioma tumours are know to be very
necrotic (25). Furthermore, the species difference for
cells (C6, rat) and host (mice) in this work would be
expected to generate an immune response with con-
comitant macrophage invasion which could also further
increase tumour necrosis. All tumours shown in Fig. 6
had apparent necrotic regions as may be deduced from
CE-T1 and fusion images by the typical “ring enhance-
ment” pattern seen (18), using both contrast agents.
Furthermore, those tumours appear to contain poorly
perfused regions as pointed by the selective slowentry of
Gd-DTPA in such areas (as found in time-course curves,
results not shown). As expected, the single C6 tumour
studied appeared to be more necrotic (slower entry
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and longer washout time for Gd-DTPA) than GL261
tumours, with some positive contrast already observed
in the control T1 images. In agreement with this, the
Fe(phos) solution producedhigher and longer lasting con-
trast enhancement in the C6 tumour than in any of the
GL261 tumours studied. This result could be interpreted
as due to higher extracellular Pi the more necrotic the
tumour is. In this respect, it may be of interest to inves-
tigate the performance of Fe(phos) under conditions in
which hyperphosphatemia is expected, e.g., in the
Tumour Lysis Syndrome (TLS), situation which nor-
mally follows chemotherapy treatment of tumours (26),
or for cell tracking applications (28,29), due to the fact
that intracellular Pi concentration is normally much
higher than extracellular Pi.
Conclusions
Fe(phos) solutions present interesting relaxometric prop-
erties. For a given initial concentration of Fe8, and by
varying the concentration of the phosphate salt, the
ri value increases to maximal values of r1 = 2.5 and
r2 = 2.9mM−1s−1 for a [HPO2−4 ]/[Fe8] = 1, 000. Mag-
netic measurements of Fe(phos) solutions show that the
initial Fe8 molecule is not stable and that the phosphate
concentration plays an essential role in the final sta-
bility and relaxometry properties of the new species.
Only for ratios of [HPO2−4 ]/[Fe8] ≥ 10, the possible col-
loids that are present in solution are time-stable and
its composition and/or size will depend on the con-
centration of the phosphate salt. In vitro and in vivo
toxicity studies of Fe(phos) solutions confirm the lack of
detectable toxic effects up to a concentration of 10mM
Fe8/100mM phosphate, suggesting that no toxic free
iron ions are eventually released. We have also demon-
strated that the Fe(phos) solution is well tolerated bymice
at a concentration that enables positive T1 contrast
enhancement of brain tumours albeit less efficient than
commercially available compounds, such as Gd-DTPA.
The possible application of the Fe(phos) solution for high-
lighting in vivo hyperphosphatemic regions or its poten-
tial use in angiography or cell tracking deserves further
investigation.
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